 EMERYVILLE, Calif.--BUSINESS WIRE--Adamas Pharmaceuticals, Inc. Nasdaq: ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, Effects of GOCOVRI amantadine extended-release capsules on motor aspects of experiences of daily living in people with Parkinsons disease and dyskinesia in the peer-reviewed journal of Neurology and Therapy. Th 